A Case of Oxaliplatin-Related Ocular Toxicity.
10.3341/jkos.2014.55.1.143
- Author:
Han Seok PARK
1
;
Yang Jae KIM
;
Su Jeong SONG
;
Jeong Hun BAE
Author Information
1. Department of Ophthalmology, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jhbae94@hotmail.com
- Publication Type:Case Report
- Keywords:
Electroretinogram;
Ocular toxicity;
Oxaliplatin;
XELOX
- MeSH:
Adult;
Antineoplastic Agents;
Appointments and Schedules;
Drug Therapy;
Female;
Humans;
Optic Nerve;
Photoreceptor Cells, Vertebrate;
Stomach Neoplasms;
Visual Field Tests;
Visual Fields
- From:Journal of the Korean Ophthalmological Society
2014;55(1):143-148
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report a case of oxaliplatin (Eloxatin(R))-related ocular toxicity in a patient with advanced stomach cancer. CASE SUMMARY: A 43-year-old female with advanced stomach cancer experienced visual symptoms during the treatment with oxaliplatin on a XELOX schedule (a combination of oxaliplatin and capecitabine). After 1 cycle of chemotherapy, she complained of blurred vision and visual field defects in both eyes. Visual field tests showed a bilateral concentric field defect and the electroretinogram revealed a marked reduction of responses in both eyes. On the second cycle of chemotherapy, oxaliplatin was discontinued due to suspicious ocular toxicity. Her visual symptoms improved and visual field test showed normal results 1 month after oxaliplatin discontinuation. However, 3 months after oxaliplatin discontinuation, electroretinogram remained abnormal despite the progressive improvement. CONCLUSIONS: Platinum-based antineoplastic agents such as oxaliplatin should be administered with caution because oxaliplatin can cause damage to the retinal photoreceptors and the optic nerve. Early detection of ocular toxicity and discontinuation of oxaliplatin therapy could prevent severe and irreversible visual loss.
